Sandro Halwe

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Vaccination, Vaccine Safety, Phase 1/2 +7

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Christoph Kreer, Matthias Zehner, Timm Weber et al. · Cell · 2020 · 394 citations · Full text

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Pedro M. Folegatti, Mustapha Bittaye, Amy Flaxman et al. · The Lancet Infectious Diseases · 2020 · 236 citations · Full text

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

Till Koch, Christine Dahlke, Anahita Fathi et al. · The Lancet Infectious Diseases · 2020 · 166 citations · Full text

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde et al. · Proceedings of the National Academy of Sciences · 2021 · 96 citations · Full text